CION Ameerpet
Being told the cancer began in the lining of your abdomen rather than in an ovary is disorienting — particularly if your ovaries were removed years ago. Primary peritoneal cancer is staged, treated and followed up as ovarian cancer: the same protocol, the same chemotherapy, the same genetic testing. The label describes where the disease was found, not a different illness with a different plan.
Primary peritoneal cancer begins in the peritoneum — the thin membrane lining the inside of the abdomen and covering the bowel, the liver and the pelvic organs. It is almost always a high-grade serous carcinoma, the same subtype that accounts for most ovarian cancer, and it is staged and treated on the ovarian cancer pathway.
Two things explain how a cancer with ovarian characteristics can grow on the abdominal lining while the ovaries look untouched. The peritoneum and the surface of the ovary develop from the same embryonic tissue, so they can go wrong in the same way. And more recently, careful sectioning of the fallopian tubes showed that many of these cancers begin as a microscopic lesion at the fringed end of the tube and seed the peritoneal surface long before anything is visible in an ovary. See fallopian tube cancer for how that finding reshaped the whole classification.
So the label is a statement about where the bulk of the disease sits. It is not a separate illness with its own untested treatment. Your chemotherapy, your genetic testing and your follow-up are the ovarian cancer ones, run by teams who use that protocol every week. If you take one thing from this page, take that.
Including the omentum, the fatty apron across the front of the abdomen, where deposits often gather first.
Normal in size, only minimally involved, or removed years earlier. That is what makes the recorded primary site peritoneal.
Same FIGO stages, same platinum-based chemotherapy, same BRCA and HRD testing. See the ovarian cancer guide.
Primary peritoneal cancer is not a diagnosis of exclusion — it has formal criteria. The Gynecologic Oncology Group set them out in 1993 and they are still in use: both ovaries must be normal in size or enlarged only by a benign process; disease outside the ovaries must exceed the disease on the ovarian surface; any ovarian involvement must be absent, confined to the surface, or measure less than 5 mm × 5 mm; and the tumour must be predominantly serous in type. Since 2014, FIGO has staged peritoneal carcinoma on the same system as ovarian and fallopian tube cancer, and the WHO classification treats high-grade serous carcinoma of all three sites as one entity — which is why the treatment protocol does not change with the label. Source: Bloss et al., Gynecologic Oncology (1993), GOG criteria for extraovarian peritoneal serous papillary carcinoma; FIGO Committee on Gynecologic Oncology staging classification (2014); WHO Classification of Tumours, Female Genital Tumours.
This is the comparison most people want in the first week. The short version: the two differ in where the disease is found and how far along it usually is, and barely at all in how it is treated.
| Point of comparison | Primary peritoneal cancer | Ovarian cancer |
|---|---|---|
| Where the bulk of disease sits | On the peritoneal lining and the omentum, spread across the abdomen | In or on one or both ovaries, often with peritoneal spread as well |
| The ovaries themselves | Normal in size, only minimally involved, or removed at earlier surgery | Enlarged, solid or mixed in appearance on scanning |
| Stage when it is found | Nearly always FIGO stage III or IV, because it is disseminated by definition | Anything from stage I to stage IV |
| Staging system used | The FIGO system for ovarian, tubal and peritoneal carcinoma | The same FIGO system, shared since 2014 |
| Usual first treatment | Chemotherapy first in most cases, with surgery in the middle of the course | Surgery first where all visible disease can be removed at the outset |
| Chemotherapy used | Platinum-based, the identical regimen | Platinum-based |
| Genetic testing offered | Germline BRCA and tumour HRD testing for every woman | Germline BRCA and tumour HRD testing for every woman |
*Reports sometimes say ‘ovarian’ in one line and ‘peritoneal’ in another for the same cancer. That is usually this overlap showing through rather than a mistake — ask your oncologist which primary site was recorded and why. For how this disease travels across the abdominal lining, see how ovarian cancer spreads.
The symptoms are abdominal rather than pelvic, which is one reason this diagnosis is often reached later than anyone would like.
An irritated or infiltrated peritoneum produces fluid, and that fluid — ascites — collects in the abdomen. Women describe a waistband that stopped fitting over a few weeks, a tummy that looks pregnant, clothes that no longer button, and breathlessness when lying flat, all without weight gain anywhere else.
This is not the on-and-off bloating that comes with meals or with your cycle. Ascites builds and stays. An abdomen that has been getting steadily bigger for weeks warrants a scan rather than a wait.
Feeling full after a few mouthfuls, a dull ache low in the abdomen, poor appetite, altered bowel habit, new urinary urgency, and tiredness that sleep does not fix. Each one on its own is common and almost always caused by something else entirely.
What makes the pattern matter is that it is new, present on most days, and not settling over weeks. Indigestion treatment that is not working, in a woman past 50, is a reason to examine the abdomen properly rather than to change the tablet.
A CT scan of the chest, abdomen and pelvis is usually the test that shows what is happening: fluid in the abdomen, thickened peritoneum, deposits on the omentum, and ovaries that look normal or nearly so. CA-125 is usually raised, though it is not diagnostic on its own — it also rises in liver disease, infection, fibroids and endometriosis.
Confirmation comes from fluid or tissue: cytology on drained ascitic fluid, or an image-guided biopsy of a peritoneal or omental deposit. Immunohistochemistry then confirms the serous subtype and the Mullerian origin. The pathologist records the primary site as peritoneal when the ovaries are essentially uninvolved and the disease outside them clearly predominates.
This is the part that unsettles people most, and it is better said plainly. Removing the tubes and ovaries lowers the risk of this family of cancers substantially, but it does not take it to zero, because the peritoneal lining is still in place. Primary peritoneal cancer is the reason women who have had risk-reducing surgery are still asked to report persistent abdominal symptoms rather than assume they are covered.
It does not mean the surgery failed or was wasted. The risk after that operation is far lower than the risk without it. It means the remaining risk is small rather than absent, and it is better to know that than to be blindsided by it years later.
By definition this cancer is already spread across the peritoneal lining by the time it is identified, so the FIGO stage assigned is usually III or IV. That reads alarmingly on a report, and it is worth separating what the number describes from what it predicts.
Stage describes distribution — how widely the disease is spread — not how treatable it is. High-grade serous disease of the peritoneum is typically responsive to platinum-based chemotherapy, and the response often shows early, in a falling CA-125 and an abdomen that stops refilling. A stage III or IV label at diagnosis here is expected rather than exceptional.
No screening programme finds ovarian, tubal or peritoneal cancer early enough to change outcomes — not in the general population, and not in women carrying a BRCA variant. Regular CA-125 tests and ultrasound scans have been studied properly for exactly this purpose and do not deliver it. Anyone presenting them as protection is offering false comfort.
For a woman at high inherited risk, what genuinely reduces risk is surgery to remove the tubes and ovaries, timed and discussed with a genetic counsellor. Surveillance is a way of watching, not a way of protecting, and it should never be described as the latter.
These come up in almost every second-opinion consultation, and they are frequently not covered unless you ask directly.
Peritoneal, ovarian or tubal — and whether the pathologist noted how confidently that site was assigned.
For peritoneal carcinoma the answer should be yes. If the plan sounds different, ask what makes your case different.
Both are offered whatever your family history, and both decide whether maintenance therapy applies to you.
Ask which is planned and why. In peritoneal disease chemotherapy usually comes first, with surgery mid-course.
How completely disease is cleared strongly influences outcome, so the surgeon's specialty is a fair question to ask.
It applies to selected patients at interval surgery, not to everyone. Ask whether it is genuinely on the table.
If nobody has mentioned BRCA or HRD testing, treat that as a gap to raise rather than assuming it was considered and ruled out. You can also book a free second opinion and bring your reports with you.
Primary peritoneal cancer runs on the ovarian cancer protocol from the first scan to the last follow-up. Bring your reports to a free 45-minute consultation and have someone go through exactly what they say.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Chemotherapy, maintenance therapy and BRCA and HRD testing are delivered in-house at CION — see how ovarian cancer treatment is organised.
The sequence below is the ovarian cancer pathway, because that is what peritoneal carcinoma is treated on. Where each step runs in-house at CION and where it is coordinated elsewhere is stated as it comes up.
Fluid or tissue confirms the subtype, a CT scan of the chest, abdomen and pelvis maps how far the disease has spread, and a baseline CA-125 gives something to measure the response against. Where PET-CT is needed it is coordinated at partner imaging centres. The case then goes to a tumour board — medical oncology, imaging and pathology together — before any plan is settled.
In primary peritoneal cancer the disease is spread across the lining at diagnosis, so removing everything visible at the outset is often not achievable. Chemotherapy is therefore usually given first to shrink it, with surgery in the middle of the course and further chemotherapy afterwards. Where imaging suggests a complete clearance is possible straight away, surgery comes first instead. Neither route is the lesser option — the extent of disease largely decides which one you are on.
Platinum-based chemotherapy is the backbone of treatment, and high-grade serous disease of the peritoneum is typically responsive to it. The response often shows early, in a falling CA-125 and an abdomen that stops refilling with fluid. Chemotherapy is delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, so cycles can continue close to home instead of requiring long journeys while you are unwell. See how ovarian cancer treatment is organised.
The operation removes the uterus, tubes and ovaries, strips affected peritoneum, takes the omentum and clears visible deposits. How completely that is achieved is one of the strongest influences on outcome in advanced disease, which is why it belongs with a specialist gynaecologic-oncology surgeon. At CION this surgery is coordinated with specialist partner centres and may be billed there — we would rather say so plainly now than have you discover it later.
Because this disease lives on the peritoneal surface, treatment delivered into the abdomen itself is a reasonable thing to ask about. HIPEC — heated chemotherapy given during surgery — and intraperitoneal chemotherapy are used in selected patients, typically at interval surgery, and not as routine for everyone. Both are coordinated at specialist partner centres and may be billed there, and whether either applies to you is a tumour-board decision rather than a preference.
Germline BRCA testing is offered to essentially every woman with peritoneal, ovarian or tubal carcinoma, whatever her family history, because the result guides her own treatment as well as her relatives' risk. Tumour HRD testing asks a related question about the cancer's DNA repair. Both, with genetic counselling, are delivered in-house at CION — as is the PARP-inhibitor-class maintenance therapy that may follow first-line chemotherapy to extend the period before the disease returns.
Fluid that keeps returning can be drained for symptom relief, and it usually settles once chemotherapy begins to work. Weight loss and poor appetite are treated as part of the plan rather than as an afterthought, and nutrition support is in-house. Follow-up combines symptom review, examination and CA-125, which is genuinely informative in this disease because it is nearly always raised at diagnosis.
*Every decision above is made against your stage, your pathology and your general health. This page describes the standard pathway, not a plan for any individual.
The most useful thing a first consultation does after this diagnosis is unhurried translation — of the pathology wording, the CT report, and what the plan on your discharge summary actually commits you to. Your first consultation at CION is free and runs to about 45 minutes. Bring the pathology report and any imaging discs you have; they answer more in ten minutes than an hour of conversation without them.
What is delivered in-house at CION is the medical oncology side: chemotherapy and PARP-inhibitor-class maintenance therapy across 35+ centres in Telangana and Andhra Pradesh, along with genetic counselling and BRCA and HRD testing, nutrition support and long-term follow-up. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there, as are HIPEC, intraperitoneal chemotherapy and PET-CT where they are indicated. Outcomes for this surgery are better in specialist hands, which is precisely why it is arranged that way rather than kept in-house.
On survival figures, one honest note. CION publishes its own one-year survival alongside the national figure so the comparison is visible rather than implied: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. That covers the whole treated population — ovarian, tubal and peritoneal disease counted together — and it is a one-year figure, not a cure rate and not a prediction for you. Published survival numbers specific to primary peritoneal cancer mislead badly in any case: they are historical, they average across substages, and they mix women who had a complete surgical clearance with women who did not. Your own outlook is a conversation with your oncologist, who can speak to your actual situation.
Free, unhurried, and long enough to read the pathology report with you line by line rather than summarise it.
BRCA and HRD testing, chemotherapy and maintenance therapy all in-house, with no weeks lost between steps.
Medical oncology, imaging and pathology review the case together before any plan is settled.
Cytoreduction, HIPEC and intraperitoneal chemotherapy at specialist partner centres, where they may also be billed.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups rather than individuals — discuss your own prognosis with your treating oncologist.
Primary peritoneal cancer is a cancer that begins in the peritoneum, the thin membrane lining the inside of the abdomen and covering the bowel, liver and pelvic organs. It is almost always a high-grade serous carcinoma, which is the same subtype that accounts for most ovarian cancer. The ovaries are normal in size, only minimally involved, or have already been removed, and that is what makes the recorded primary site peritoneal rather than ovarian. Many of these cancers are now thought to start as a microscopic lesion at the fringed end of a fallopian tube and seed the peritoneal surface early. Whatever the origin, it is staged and treated on the ovarian cancer pathway.
The difference is where the disease sits, not what it is or how it is treated. In primary peritoneal cancer the bulk of the tumour is on the abdominal lining and the omentum while the ovaries look essentially normal; in ovarian cancer the tumour is in or on the ovary itself, often with peritoneal spread as well. The Gynecologic Oncology Group criteria decide which label applies, based on how little ovarian involvement there is. Beyond the label, almost nothing changes. FIGO has staged both on one system since 2014, the chemotherapy is the same platinum-based treatment, BRCA and HRD testing is offered either way, and follow-up is identical. One practical difference: peritoneal disease is nearly always found at stage III or IV, so chemotherapy more often comes before surgery.
Yes, and it is the main reason this diagnosis exists as a separate label. Removing the tubes and ovaries lowers the risk of this family of cancers a great deal, but it cannot take it to zero, because the peritoneal lining that can also give rise to the disease is still in place. That is why women who have had risk-reducing surgery, particularly BRCA carriers, are still asked to report persistent abdominal bloating, swelling or early fullness rather than assume they are covered. It does not mean the operation failed or was pointless; the risk afterwards is far lower than the risk without it. It means the remaining risk is small rather than absent, and worth knowing about.
Abdominal swelling is usually the first thing noticed, because the irritated peritoneum produces fluid that collects in the abdomen. Women describe a waistband that stopped fitting over a few weeks, a tummy that looks pregnant, and breathlessness when lying flat, with no weight gain elsewhere. Alongside that come persistent bloating, feeling full after a few mouthfuls, poor appetite, vague lower abdominal pain, altered bowel habit and new urinary urgency. None of these is specific, and each is far more often caused by something benign. The pattern is what matters: new, present on most days, and not settling over weeks. Steady abdominal enlargement over weeks deserves a scan rather than a wait.
No. There is no effective screening for ovarian, fallopian tube or peritoneal cancer in any group of women, and this is worth saying plainly because the misunderstanding is so widespread. Regular CA-125 blood tests and ultrasound scans have been studied carefully for this purpose and do not find the disease early enough to change outcomes. That remains true for women who carry a BRCA1 or BRCA2 variant, where believing otherwise causes the most harm. For a woman at high inherited risk, the intervention that genuinely reduces risk is surgery to remove the tubes and ovaries, timed and discussed with a genetic counsellor. Surveillance is a way of watching for problems, not a way of preventing them, and nobody should be told otherwise.
The first consultation is free and runs to about 45 minutes, so bring your pathology report and any imaging discs. Chemotherapy and PARP-inhibitor-class maintenance therapy are delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, and so are genetic counselling and BRCA and HRD testing, which is what determines whether maintenance therapy applies to you. Nutrition support and long-term follow-up are in-house as well. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there, as are HIPEC, intraperitoneal chemotherapy and PET-CT where they are indicated. Every case that raises a question goes to a tumour board rather than being decided by one clinician alone.